Learn details of Autism Pipeline Review H2 2017 which provides pipeline therapeutics and drug development for Autism with dormant and discontinued projects by pharmaceutical companies including 4D Pharma PLC, Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc, Aevi Genomic Medicine Inc, AgeneBio Inc, Anima Biotech Ltd, APeT Holding BV, BioCrea GmbH, BioHealthonomics Inc, BrainStorm Cell Therapeutics and more.
Autism Pipeline Review H2 2017 provides an overview of Autism Pipeline landscape. Autism is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from Autism is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The Autism pipeline guide reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 4, 1, 18, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.
Purchase This Autism Pipeline Review H2 2017 Report of 138 Pages with Company profiles and Pipeline Drugs Analysis at http://www.reportsnreports.com/purchase.aspx?name=1125805 .
Report provides comprehensive information on the therapeutics under development for Autism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Autism pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Get Discount on This Report at: http://www.reportsnreports.com/contacts/discount.aspx?name=1125805 .
The pipeline guide provides a snapshot of the global therapeutic landscape of Autism and reviews pipeline therapeutics for Autism by companies and universities/research institutes based on information derived from company and industry-specific sources. This report covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages also features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. Key companies involved in Autism therapeutics and enlist all their major and minor projects also reviewed in Autism pipeline guide.
Autism Pipeline by Companies Analyzed in report: 4D Pharma PLC, Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc, Aevi Genomic Medicine Inc, AgeneBio Inc, Anima Biotech Ltd, APeT Holding BV, BioCrea GmbH, BioHealthonomics Inc, BrainStorm Cell Therapeutics Inc, Confluence Pharmaceuticals LLC, Coronis NeuroSciences Ltd, Curemark LLC, DRI Biosciences Corp, F. Hoffmann-La Roche Ltd, GW Pharmaceuticals Plc, Heptares Therapeutics Ltd, Immuron Ltd, Intra-Cellular Therapies Inc, Leading BioSciences Inc.
Autism Pipeline Drugs Discussed: acamprosate calcium, ACT-01, ADX-71441, ADX-88178, Antibody to Inhibit Lipopolysaccharide for Autism, aripiprazole, ASD-002, Biologics for Autism, CB-0306, CM-AT, CP-102, Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome, fasoracetam, GWP-42006, histamine dihydrochloride, HTL-14242, IMM-124E, L-179, lumateperone tosylate, lurasidone hydrochloride, MD-1103, niacinamide CR, NurOwn, oxytocin, PAM-28, Recombinant Insulin Like Growth Factor 1, RG-7314, SERx-519, SF-999, Small Molecule to Agonize GABRA5 Receptor for CNS Disorders, TTA-121.
Featured News & Press Releases
Apr 19, 2017: BrainStorm Announces Publication of NurOwn Autism Research Study
Feb 23, 2017: Curemark Announces Further Expansion of Clinical Sites For Its Phase 3 Clinical Trial for Children with Autism – The BlUm Study
Sep 22, 2016: Blum Study – A Phase 3 Clinical Trial for Children with Autism
Jul 20, 2016: Immuron to Cooperate with Leading Australian Universities on Autism Research
Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch
Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus’ Once-Weekly Transdermal Aripiprazole
May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism
Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment
Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism
Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors
Aug 06, 2012: Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism
May 31, 2012: Study Reports New Treatment For Irritability In Autism
Dec 07, 2011: Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism
Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism
Oct 27, 2010: Curemark Adds Two Autism Trial Sites In California.
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Autism – Overview
Autism – Therapeutics Development
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Autism – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Autism – Companies Involved in Therapeutics Development.
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441